OneSource Speci. Q3 FY26 Earnings Call — Analysis (NSE: ONESOURCE)
OneSource defers DDC revenues due to Canadian semaglutide approval delays but reiterates FY28 guidance of $400M revenue, emphasising robust demand and customer forecast upgrades.
The take
Q3FY26 Revenue ₹290.3 Cr ( −26% YoY ) . New guidance — FY27 ddc csa revenue in fy27 material CSA revenues, H2 > H1 . New story: Capacity Build‑out Arms Race .
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹290.3 Cr | −26% | yoy · Q3FY26 |
| EBITDA | ₹17.3 Cr | yoy · Q3FY26 · Negative operating leverage due to revenue shortfall | |
| Adjusted PAT | -₹47.2 Cr | yoy · Q3FY26 · Excludes exceptional items relating to scheme intangibles | |
| Customer Advances | ₹250 Cr | point_in_time · Q3FY26 · As of Dec-2025 | |
| Effective Interest Rate | <9% | −200 bps | yoy · Q3FY26 |
What management committed to
- We expect the next two quarters to remain relatively soft. — relatively soft, Q4FY26 and Q1FY27
- FY27 will mark the beginning of material CSA revenues with H2 significantly stronger than H1. — material CSA revenues, H2 > H1, FY27
- We expect a Q4 FY27-analyzed exit run rate for both revenues and EBITDA to be a good reflection of near-close FY28 guidance numbers. — near-close FY28 guidance ($400M revenue, $160M EBITDA), Q4FY27
- We anticipate us to be able to get the final all regulatory approvals in place by third quarter of FY27. — Q3FY27
- By end of the financial year FY27, we would be having, almost, let's say, installed almost 200 odd million [units]. — 200 million units, FY27
- This [oncology] product should be launched by our customer in the next one quarter. — Q1FY27
- 1.5 [x net debt to EBITDA] is more a guided number [peak leverage]. — less than 1.5x, FY28
How the narrative shifted
- Regulatory Ambiguity & Revenue‑Recognition Gap: The Canada delay is now explicitly acknowledged with a timeline (Feb-May), and the narrative of 'ambiguity' is used to explain soft near-term performance.
- Capacity Build‑out Arms Race: Timeline shifted from CY26 to FY27, but conviction remains high with specific progress.
- Geographic & Customer De‑risking Beyond Canada: India now explicitly positioned as a market we will be present in at opening, reducing over-reliance on Canada.
- Biologics Resurgence as Second Engine: Linked to specific regulatory catalysts (FDA biosimilar guidelines, Biosecure Act) and a concrete new customer.
- Inorganic Integration & Scale: Timeline provided; no change in story.
- CDMO Moat: End‑to‑End & Multi‑Modality: Less airtime given to the moat argument.
- Semaglutide Global TAM Inflection: Now backed by explicit statement of upward forecast revisions.
- Working Capital & Debt Transience: Added specific debt target and timeline.
- Sterile Injectable Capacity Upgrade & Shutdown: New thread introduced in this call.
- Partner Collaboration & Contract Flexibility: New approach to managing partner relationships emerging.
Operational commentary
- Q3 performance impacted by deferred DDC revenues due to Canadian regulatory approval delays for semaglutide for key partners like Dr. Reddy's.
- Strategic decision to prioritise commercial supply capacity over new DDC MSAs, leading to a deliberate reduction in MSA bookings.
- Over ₹700 Cr capex plan progressing; nearly $75M of the $100M planned investment for the flagship DDC site already committed.
- Flagship DDC site doubled its workforce YTD by adding approximately 300 new FTEs.
- Sterile injectable facility in Bangalore to undergo a four-month shutdown for capacity expansion in lyophilisation and pre-filled syringes; impact deemed non-material.
- Biologics business seeing strong tailwinds from Biosecure Act and FDA biosimilar guideline changes; RFP funnel up 4x YoY and a new US-based biosimilar customer onboarded.
- Soft gelatine business secured first oncology asset, an NDA product partnered with a top-10 US generic company.
- Company earned an EcoVadis Bronze Medal for sustainability.
- 36 successful regulatory and customer inspections completed YTD, including a positive recent inspection at the flagship DDC site.
Analyst Q&A
Q. What does the business gain from renegotiating take-or-pay contracts with large customers?
We gain long-term partnership and visibility beyond three years by showing flexibility during regulatory delays, which supports our $100M capex investment decision.
Q. What is the expected peak debt given delays, and has the net cash positive outlook changed?
On the base business steady state, we expect to be debt-free by FY28. The 1.5x debt-to-EBITDA guidance is an internal ceiling, factoring in potential additional investments for biologics and beachheads in the US/Europe.
Q. Does pricing differ for a customer based on the end-market geography, such as India vs. Canada?
Pricing is fixed and based solely on volume tiers, not the end market. Market geography is completely immaterial to our pricing.
Q. When will supplies reflect in numbers after a customer receives regulatory approval in Canada?
Supplies will start fairly soon after approvals come, as some aspects must be put on the individual pen post-approval. Volume ramp-up will take its time.
Q. What is the progress on the acquisition of two injectable facilities, and what is the closure timeline?
The process is moving forward well. A discussion is ongoing between the Stock Exchange and SEBI, and we anticipate final regulatory approvals by the third quarter of FY27.
Research and educational content only. Not investment advice.